After months of waiting, Eli Lilly and Company might soon get its hands on the radiopharmaceutical specialist POINT Biopharma Global Inc.. In October, Lilly bid $1.4bn to acquire Point, but the majority of the smaller group’s investors declined to tender their shares. It is likely that they wanted to wait for data from the Phase III trial of Point’s prostate cancer radioligand PNT2002; if this were to be a huge success, Point’s shareholders could demand Lilly up its bid.
Prostate Cancer Disappointment Means Lilly Might Finally Get The Point
Point Biopharma’s radiopharmaceutical lags Novartis’s on PFS, and its commercial viability may be limited.
More from Clinical Trials
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
More from R&D
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.